Cargando…

Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

PURPOSE: The aim of this study was to determine whether CD8(+) T lymphocyte and its checkpoint-associated module programmed cell death protein 1 (PD-1)/main ligand of PD-1 (PD-L1) pathway impact overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Jiaxi, Xi, Wei, Zhu, Yanjun, Wang, Hang, Hu, Xiaoyi, Guo, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138960/ https://www.ncbi.nlm.nih.gov/pubmed/30237743 http://dx.doi.org/10.2147/CMAR.S172039

Ejemplares similares

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Wang, Zhaojuan, et al.
Publicado: (2023)

Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients
por: Xu, Xianglai, et al.
Publicado: (2023)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia
por: Taghiloo, Saeid, et al.
Publicado: (2017)

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
por: Ma, Weijie, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Target B Lymphocytes
por: Upfold, Nikki Lyn Esnardo, et al.
Publicado: (2023)

Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
por: Diehl, Adam, et al.
Publicado: (2017)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
por: Liu, Chang, et al.
Publicado: (2021)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yang, Yuanquan, et al.
Publicado: (2022)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
por: Talaat, Iman M., et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

TYRO protein tyrosine kinase-binding protein predicts favorable overall survival in osteosarcoma and correlates with antitumor immunity
por: Xu, Hai-Ru, et al.
Publicado: (2022)

Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
por: Wang, Hong-Kai, et al.
Publicado: (2016)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)

Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice
por: Chen, Jia-Shiong, et al.
Publicado: (2022)

Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
por: Yang, Min, et al.
Publicado: (2020)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
por: Miyoshi, Yasuo, et al.
Publicado: (2020)

Association between absolute lymphocyte count and overall mortality in patients with surgically resected gastric cancer
por: Park, Se Jun, et al.
Publicado: (2021)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer
por: Cherif, Boutheina, et al.
Publicado: (2021)

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase
por: Mattila, Elina, et al.
Publicado: (2010)

Effects of Cabozantinib, a small molecule tyrosine kinase inhibitor, on the immune permissiveness of the tumor microenvironment and immune-mediated killing of tumor cells
por: Kwilas, Anna R, et al.
Publicado: (2014)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia
por: Cerreto, Marina, et al.
Publicado: (2023)

Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
por: Park, Tae Ju, et al.
Publicado: (2016)

Neutrophil and lymphocyte counts at diagnosis are associated with overall survival of pancreatic cancer: A retrospective cohort study
por: Xiao, Yuanyuan, et al.
Publicado: (2016)

Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor
Publicado: (1996)

Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
por: Rohrs, Jennifer A., et al.
Publicado: (2016)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
por: Chen, Ruyin, et al.
Publicado: (2022)

CD8(+) T Lymphocyte Coexpression Genes Correlate with Immune Microenvironment and Overall Survival in Breast Cancer
por: Jiang, Jialing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mfj61bm39ucl06gsb54g5ln4pa